Tegal Corp (CLRX) 1.84 $CLRX
Littany Lane Investments Reiterates Speculative Buy on CollabRx, Inc., Price Target $2.00 - $3.50. Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Feb 13, 6:00AM CST
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care
CLRX: 1.84 (+0.04)
Littany Lane Investments Analyst Initiates Coverage of CollabRx with Near Term Target of $2-$3.50 Issued By BrokerBank Securities, Inc.
PR Newswire - Tue Feb 03, 6:00AM CST
Littany Lane Investments analyst initiates coverage of CollabRx, Inc. (NASDAQ: CLRX) with near term price target of $2.50-$3.50/share. CollabRx recently announced an LOI to merge with Medytox Solutions on January 22nd, 2015. Medytox could potentially add over $52.5M in annual revenue to CollabRx's bottom line based on the most recent annual report issued by Medytox (Year ending December 31st, 2013).
CLRX: 1.84 (+0.04)
Market Maker Surveillance Report. CRK, NES, PEGFF, BBEP, PSTR, CLRX, Winning Stocks With Lowest Price Friction For Monday, February 2nd 2015
M2 - Tue Feb 03, 3:15AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5214 companies with "abnormal" market making, 3994 companies with positive Friction Factors and 2396 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Comstock Resources Inc (NYSE:CRK), M/S GBCPN 3 GBL INDS (NYSE:NES), PACIFIC RUBIALES ENERGY CORP (OTC
EGFF), BreitBurn Energy Partners LP (NASDAQ:BBEP), PostRock Energy Corp (NASDAQ STR), (NASDAQ:CLRX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NES: 3.52 (+0.13), CLRX: 1.84 (+0.04), PSTR: 4.63 (+0.14), BBEP: 7.85 (+0.32), CRK: 6.09 (+0.46)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 11:49AM CST
FRO: 2.96 (+0.07), LUNA: 1.48 (-0.01), NES: 3.52 (+0.13), PSTI: 2.91 (+0.01), MILL: 2.07 (+0.09), TBIO: 2.91 (+0.01), SONS: 17.69 (-0.01), NKA: 1.68 (+0.13), YOD: 2.22 (+0.04), ARDX: 17.14 (+0.71), SR: 1.25 (+0.08), OHGI: 1.82 (-0.12), LBIX: 3.43 (-0.06), DQ: 21.04 (-0.21), CLRX: 1.84 (+0.04), PSTR: 4.63 (+0.14), HART: 2.92 (+0.34), WAC: 20.29 (+2.57), CRK: 6.09 (+0.46), SRT: 8.85 (+0.07)
CollabRx up on improved funding outlook from potential business combo
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 11:02AM CST
CLRX: 1.84 (+0.04)
CollabRx announces non-binding letter of intent for proposed business combination with Medytox Solutions
M2 - Fri Jan 23, 8:03PM CST
Medical information company CollabRx (NasdaqCM:CLRX) reported on Thursday the execution of a non-binding letter of intent to negotiate a potential business combination with Medytox Solutions (OTCBB:MMMS).
CLRX: 1.84 (+0.04)
CollabRx and Medytox Solutions Sign Non-Binding Letter of Intent for Possible Business Combination
Marketwired - Thu Jan 22, 5:30AM CST
CollabRx, Inc. (NASDAQ: CLRX) and Medytox Solutions, Inc. (OTCQB: MMMS) ("Medytox"
have entered into a non-binding letter of intent to negotiate a potential business combination. Also, CollabRx and Medytox announced that they have entered into agreements that would secure funding needed by CollabRx to continue to operate while the parties negotiate a potential business combination. The potential business combination is subject to, among other things, due diligence, the execution of a definitive agreement, necessary Board of Directors and stockholder approvals and other customary conditions.
CLRX: 1.84 (+0.04)
CollabRx Receives NASDAQ Listing Determination; Intends to Request Hearing
GlobeNewswire - Tue Jan 20, 3:06PM CST
CollabRx, Inc. (Nasdaq:CLRX) ("the Company" announced that it received a letter from the NASDAQ Listing Qualifications Staff indicating that, unless the Company timely requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel" , the Company's securities would be delisted from The NASDAQ Capital Market due to the Company's non-compliance with NASDAQ Listing Rule 5550(b)(1) (the "Rule" . The Company intends to timely request a hearing before the Panel, at which hearing the Company will present its plan to evidence compliance with the Rule, which requires the Company to maintain a minimum of $2.5 million in stockholders' equity. The Company's common stock will continue to trade on The NASDAQ Capital Market under the symbol "CLRX" pending completion of the hearing process and the expiration of any extension period granted by the Panel.
CLRX: 1.84 (+0.04)
CollabRx Announces Receipt of NASDAQ Notice of Non-Compliance With Rule 5550(b)(1)
GlobeNewswire - Wed Dec 03, 3:01PM CST
CollabRx, Inc. (Nasdaq:CLRX) (herein "CLRX" or "the Company" , announced today that it received a letter from the NASDAQ OMX GROUP ("Nasdaq" stating that the Company is in non-compliance with the Nasdaq Capital Market's Listing Rule 5550(b)(1). That rule requires the Company to maintain a minimum stockholder's equity of $2,500,000 for continued listing.
CLRX: 1.84 (+0.04)
CollabRx Announces Receipt of NASDAQ Notice of Bid Price Deficiency
GlobeNewswire - Mon Nov 24, 6:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) (herein "CLRX" or "the Company" , announced today that it received a letter from the NASDAQ OMX GROUP ("Nasdaq" stating that the bid price of the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2).
CLRX: 1.84 (+0.04)
CollabRx EPS of -$0.35
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:28PM CST
CLRX: 1.84 (+0.04)
CollabRx Reports Second Quarter Fiscal Year 2015 Financial Results
GlobeNewswire - Thu Nov 13, 3:00PM CST
CollabRx, Inc. (the "Company" (Nasdaq:CLRX) announces financial results and business highlights for the second quarter of fiscal year 2015, which ended September 30, 2014.
CLRX: 1.84 (+0.04)
CollabRx and Cartagenia Partner in Interpretation Support and Reporting of Genetic Sequencing-Based Tests for Cancer
PRWeb - Mon Nov 10, 8:04AM CST
CollabRx, Inc. (NASDAQ: CLRX) today announced a partnership with Cartagenia, Inc. to provide and promote to the clinical laboratory market an end-to-end software solution to support clinicians and pathologists with clinical genetic testing and reporting in oncology, including next-generation sequencing (NGS) -based tests. Cartagenia is a leader in providing genetics labs and clinicians with software-based workflow support for variant assessment support, lab reporting, and integration of clinical knowledge-bases. Combined with CollabRx's industry-leading decision support solutions in oncology, the partnership will enable clinical and pathology laboratories to generate automated workflows allowing them to quickly and efficiently analyze and report on NGS test results in cancer by providing integrated access to CollabRx's highly credible medical and scientific knowledge with their own proprietary information to create physician- ready reports.
CLRX: 1.84 (+0.04)
Cartagenia Partners with CollabRx to Provide Pathology Laboratories and Cancer Centers Access to Personalized Information on Therapeutic Options
PR Newswire - Mon Nov 10, 8:00AM CST
Cartagenia, leader in providing genetic labs and clinicians with software-based workflow support for variant assessment, lab reporting, and access of relevant knowledge-bases, today announced a partnership with CollabRx that will provide Cartagenia's customers access to CollabRx's industry-leading treatment information resources and services.
CLRX: 1.84 (+0.04)
CollabRx and Collaborators at Leading Academic Centers Publish Clinical Decision Support Model for Precision Oncology
PRWeb - Wed Nov 05, 8:11AM CST
CollabRx, Inc. (NASDAQ: CLRX), a leading provider of clinical decision support solutions in oncology, today announced the publication of a clinical decision support model for oncology as an advance publication in the current online edition of the open-access journal Oncoscience.1 The publication titled "A framework for genomic biomarker actionability and its use in clinical decision making" was co-authored by senior members of CollabRx's scientific team in collaboration with clinical researchers and physicians at the University of California, San Diego, the University of Texas MD Anderson Cancer Center, the Huntsman Cancer Institute, Banner MD Anderson Cancer Center, and the Vall d'Hebron Institut d'Oncologia, Universitat Autonoma of Barcelona.
CLRX: 1.84 (+0.04)
CollabRx Editor-in-Chief & CMO George D. Lundberg, MD Wins 2014 ASCP Ward Burdick Award for Distinguished Service to Pathology
GlobeNewswire - Fri Oct 17, 8:17AM CDT
via PRWEB - CollabRx, Inc. (Nasdaq:CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, announced that George D. Lundberg, MD, the Company's editor-in-chief, chief medical officer and chair of its Editorial Advisory Board, has won the 2014 Ward Burdick Award for Distinguished Service to Pathology from the Board of Directors of the American Society for Clinical Pathology (ASCP). Dr. Lundberg was presented with his award during the ASCP Annual Meeting in Tampa, Florida on October 9.
CLRX: 1.84 (+0.04)
Littany Lane Investments Reiterates Speculative Buy on CollabRx, Inc., Price Target $2.00 - $3.50. Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Feb 13, 6:00AM CST
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care
CLRX: 1.84 (+0.04)
Littany Lane Investments Analyst Initiates Coverage of CollabRx with Near Term Target of $2-$3.50 Issued By BrokerBank Securities, Inc.
PR Newswire - Tue Feb 03, 6:00AM CST
Littany Lane Investments analyst initiates coverage of CollabRx, Inc. (NASDAQ: CLRX) with near term price target of $2.50-$3.50/share. CollabRx recently announced an LOI to merge with Medytox Solutions on January 22nd, 2015. Medytox could potentially add over $52.5M in annual revenue to CollabRx's bottom line based on the most recent annual report issued by Medytox (Year ending December 31st, 2013).
CLRX: 1.84 (+0.04)
Market Maker Surveillance Report. CRK, NES, PEGFF, BBEP, PSTR, CLRX, Winning Stocks With Lowest Price Friction For Monday, February 2nd 2015
M2 - Tue Feb 03, 3:15AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5214 companies with "abnormal" market making, 3994 companies with positive Friction Factors and 2396 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Comstock Resources Inc (NYSE:CRK), M/S GBCPN 3 GBL INDS (NYSE:NES), PACIFIC RUBIALES ENERGY CORP (OTC
EGFF), BreitBurn Energy Partners LP (NASDAQ:BBEP), PostRock Energy Corp (NASDAQ STR), (NASDAQ:CLRX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . NES: 3.52 (+0.13), CLRX: 1.84 (+0.04), PSTR: 4.63 (+0.14), BBEP: 7.85 (+0.32), CRK: 6.09 (+0.46)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 11:49AM CST
FRO: 2.96 (+0.07), LUNA: 1.48 (-0.01), NES: 3.52 (+0.13), PSTI: 2.91 (+0.01), MILL: 2.07 (+0.09), TBIO: 2.91 (+0.01), SONS: 17.69 (-0.01), NKA: 1.68 (+0.13), YOD: 2.22 (+0.04), ARDX: 17.14 (+0.71), SR: 1.25 (+0.08), OHGI: 1.82 (-0.12), LBIX: 3.43 (-0.06), DQ: 21.04 (-0.21), CLRX: 1.84 (+0.04), PSTR: 4.63 (+0.14), HART: 2.92 (+0.34), WAC: 20.29 (+2.57), CRK: 6.09 (+0.46), SRT: 8.85 (+0.07)
CollabRx up on improved funding outlook from potential business combo
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 11:02AM CST
CLRX: 1.84 (+0.04)
CollabRx announces non-binding letter of intent for proposed business combination with Medytox Solutions
M2 - Fri Jan 23, 8:03PM CST
Medical information company CollabRx (NasdaqCM:CLRX) reported on Thursday the execution of a non-binding letter of intent to negotiate a potential business combination with Medytox Solutions (OTCBB:MMMS).
CLRX: 1.84 (+0.04)
CollabRx and Medytox Solutions Sign Non-Binding Letter of Intent for Possible Business Combination
Marketwired - Thu Jan 22, 5:30AM CST
CollabRx, Inc. (NASDAQ: CLRX) and Medytox Solutions, Inc. (OTCQB: MMMS) ("Medytox"
have entered into a non-binding letter of intent to negotiate a potential business combination. Also, CollabRx and Medytox announced that they have entered into agreements that would secure funding needed by CollabRx to continue to operate while the parties negotiate a potential business combination. The potential business combination is subject to, among other things, due diligence, the execution of a definitive agreement, necessary Board of Directors and stockholder approvals and other customary conditions. CLRX: 1.84 (+0.04)
CollabRx Receives NASDAQ Listing Determination; Intends to Request Hearing
GlobeNewswire - Tue Jan 20, 3:06PM CST
CollabRx, Inc. (Nasdaq:CLRX) ("the Company"
announced that it received a letter from the NASDAQ Listing Qualifications Staff indicating that, unless the Company timely requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel" , the Company's securities would be delisted from The NASDAQ Capital Market due to the Company's non-compliance with NASDAQ Listing Rule 5550(b)(1) (the "Rule" . The Company intends to timely request a hearing before the Panel, at which hearing the Company will present its plan to evidence compliance with the Rule, which requires the Company to maintain a minimum of $2.5 million in stockholders' equity. The Company's common stock will continue to trade on The NASDAQ Capital Market under the symbol "CLRX" pending completion of the hearing process and the expiration of any extension period granted by the Panel. CLRX: 1.84 (+0.04)
CollabRx Announces Receipt of NASDAQ Notice of Non-Compliance With Rule 5550(b)(1)
GlobeNewswire - Wed Dec 03, 3:01PM CST
CollabRx, Inc. (Nasdaq:CLRX) (herein "CLRX" or "the Company"
, announced today that it received a letter from the NASDAQ OMX GROUP ("Nasdaq" stating that the Company is in non-compliance with the Nasdaq Capital Market's Listing Rule 5550(b)(1). That rule requires the Company to maintain a minimum stockholder's equity of $2,500,000 for continued listing. CLRX: 1.84 (+0.04)
CollabRx Announces Receipt of NASDAQ Notice of Bid Price Deficiency
GlobeNewswire - Mon Nov 24, 6:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) (herein "CLRX" or "the Company"
, announced today that it received a letter from the NASDAQ OMX GROUP ("Nasdaq" stating that the bid price of the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). CLRX: 1.84 (+0.04)
CollabRx EPS of -$0.35
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:28PM CST
CLRX: 1.84 (+0.04)
CollabRx Reports Second Quarter Fiscal Year 2015 Financial Results
GlobeNewswire - Thu Nov 13, 3:00PM CST
CollabRx, Inc. (the "Company"
(Nasdaq:CLRX) announces financial results and business highlights for the second quarter of fiscal year 2015, which ended September 30, 2014. CLRX: 1.84 (+0.04)
CollabRx and Cartagenia Partner in Interpretation Support and Reporting of Genetic Sequencing-Based Tests for Cancer
PRWeb - Mon Nov 10, 8:04AM CST
CollabRx, Inc. (NASDAQ: CLRX) today announced a partnership with Cartagenia, Inc. to provide and promote to the clinical laboratory market an end-to-end software solution to support clinicians and pathologists with clinical genetic testing and reporting in oncology, including next-generation sequencing (NGS) -based tests. Cartagenia is a leader in providing genetics labs and clinicians with software-based workflow support for variant assessment support, lab reporting, and integration of clinical knowledge-bases. Combined with CollabRx's industry-leading decision support solutions in oncology, the partnership will enable clinical and pathology laboratories to generate automated workflows allowing them to quickly and efficiently analyze and report on NGS test results in cancer by providing integrated access to CollabRx's highly credible medical and scientific knowledge with their own proprietary information to create physician- ready reports.
CLRX: 1.84 (+0.04)
Cartagenia Partners with CollabRx to Provide Pathology Laboratories and Cancer Centers Access to Personalized Information on Therapeutic Options
PR Newswire - Mon Nov 10, 8:00AM CST
Cartagenia, leader in providing genetic labs and clinicians with software-based workflow support for variant assessment, lab reporting, and access of relevant knowledge-bases, today announced a partnership with CollabRx that will provide Cartagenia's customers access to CollabRx's industry-leading treatment information resources and services.
CLRX: 1.84 (+0.04)
CollabRx and Collaborators at Leading Academic Centers Publish Clinical Decision Support Model for Precision Oncology
PRWeb - Wed Nov 05, 8:11AM CST
CollabRx, Inc. (NASDAQ: CLRX), a leading provider of clinical decision support solutions in oncology, today announced the publication of a clinical decision support model for oncology as an advance publication in the current online edition of the open-access journal Oncoscience.1 The publication titled "A framework for genomic biomarker actionability and its use in clinical decision making" was co-authored by senior members of CollabRx's scientific team in collaboration with clinical researchers and physicians at the University of California, San Diego, the University of Texas MD Anderson Cancer Center, the Huntsman Cancer Institute, Banner MD Anderson Cancer Center, and the Vall d'Hebron Institut d'Oncologia, Universitat Autonoma of Barcelona.
CLRX: 1.84 (+0.04)
CollabRx Editor-in-Chief & CMO George D. Lundberg, MD Wins 2014 ASCP Ward Burdick Award for Distinguished Service to Pathology
GlobeNewswire - Fri Oct 17, 8:17AM CDT
via PRWEB - CollabRx, Inc. (Nasdaq:CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, announced that George D. Lundberg, MD, the Company's editor-in-chief, chief medical officer and chair of its Editorial Advisory Board, has won the 2014 Ward Burdick Award for Distinguished Service to Pathology from the Board of Directors of the American Society for Clinical Pathology (ASCP). Dr. Lundberg was presented with his award during the ASCP Annual Meeting in Tampa, Florida on October 9.
CLRX: 1.84 (+0.04)
